此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

测试在成人 T 细胞白血病-淋巴瘤 (ATL) 的常规联合化疗(“EPOCH”)中加入抗癌药物来那度胺

2026年11月11日 更新者:National Cancer Institute (NCI)

来那度胺联合 EPOCH 化疗治疗 HTLV 相关成人 T 细胞白血病-淋巴瘤 (ATLL) 的 1 期研究

This phase I trial studies the side effects and best dose of lenalidomide when given together with usual combination chemotherapy (etoposide, prednisone, vincristine sulfate [Oncovin], cyclophosphamide, and doxorubicin hydrochloride [hydroxydaunorubicin hydrochloride], or "EPOCH") in treating adult T-cell leukemia-lymphoma. Lenalidomide may help shrink or slow the growth of adult T-cell leukemia-lymphoma. Drugs used in chemotherapy, such as etoposide, vincristine, cyclophosphamide, and doxorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Anti-inflammatory drugs such as prednisone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Giving lenalidomide and the usual combination chemotherapy may work better in treating adult T-cell leukemia-lymphoma compared to the usual combination chemotherapy alone.

研究概览

详细说明

PRIMARY OBJECTIVE:

I. To determine the safest and most tolerable dose and schedule of lenalidomide to combine with etoposide, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin hydrochloride) (EPOCH) chemotherapy in adult T-cell leukemia-lymphoma (ATL/ATLL).

SECONDARY OBJECTIVES:

I. To observe and record anti-tumor activity. II. To determine if lenalidomide and EPOCH activity results in significant improvement in remission rates, duration of remissions, and overall survival (OS) as compared to historical controls.

III. To determine if lenalidomide and EPOCH activity correlates with T-cell receptor (TCR) pathway gene mutational spectrum.

IV. To determine effects of lenalidomide and EPOCH on human T-cell leukemia virus type 1 (HTLV-1) proviral deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) loads.

V. To determine effects of lenalidomide and EPOCH on HTLV-1 clonality.

OUTLINE: This is a dose-escalation study of lenalidomide followed by a dose-expansion study.

INDUCTION THERAPY: Patients receive lenalidomide orally (PO) once daily (QD) on days 1-14 of 21 day cycles or days 1-21 or 1-28 of 28 day cycles. Patients receive doxorubicin hydrochloride intravenously (IV) continuously on days 1-4, vincristine sulfate IV continuously on days 1-4, etoposide IV continuously on days 1-4, prednisone PO on days 1-5, and cyclophosphamide IV over 1-4 hours on day 5. Treatment repeats every 21 or 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.

MAINTENANCE THERAPY: Patients with complete response (CR), partial response (PR), or stable disease (SD) may receive up to 2 additional cycles of lenalidomide, doxorubicin hydrochloride, vincristine sulfate, etoposide, prednisone, and cyclophosphamide at the discretion of the investigator and/or up to an additional 2 years of lenalidomide in the absence of disease progression or unacceptable toxicity.

Patients undergo bone marrow biopsy at baseline and as clinically indicated. Patients undergo positron emission tomography/computed tomography (PET/CT) or CT, tissue and blood sample collection throughout the trial and multigated acquistion scan (MUGA) and echocardiogram (ECHO) at screening.

After completion of study treatment, patients are followed up for 2 years from end of induction. Patients who do not continue on lenalidomide maintenance are followed every 3 months for up to 2 years from the end of induction, progression, withdrawal, or until death, whichever occurs first.

研究类型

介入性

注册 (估计的)

30

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Georgia
      • Atlanta、Georgia、美国、30322
        • 招聘中
        • Emory University Hospital/Winship Cancer Institute
        • 接触:
          • Site Public Contact
          • 电话号码:404-778-1868
        • 首席研究员:
          • Pamela B. Allen
      • Atlanta、Georgia、美国、30308
        • 招聘中
        • Emory University Hospital Midtown
        • 接触:
          • Site Public Contact
          • 电话号码:888-946-7447
        • 首席研究员:
          • Pamela B. Allen
    • Missouri
      • City of Saint Peters、Missouri、美国、63376
        • 招聘中
        • Siteman Cancer Center at Saint Peters Hospital
        • 接触:
        • 首席研究员:
          • Lee Ratner
      • Creve Coeur、Missouri、美国、63141
        • 招聘中
        • Siteman Cancer Center at West County Hospital
        • 接触:
        • 首席研究员:
          • Lee Ratner
      • St Louis、Missouri、美国、63110
        • 招聘中
        • Washington University School of Medicine
        • 接触:
        • 首席研究员:
          • Lee Ratner
      • St Louis、Missouri、美国、63129
        • 招聘中
        • Siteman Cancer Center-South County
        • 接触:
        • 首席研究员:
          • Lee Ratner
    • New Jersey
      • Basking Ridge、New Jersey、美国、07920
        • 招聘中
        • Memorial Sloan Kettering Basking Ridge
        • 首席研究员:
          • Steven M. Horwitz
        • 接触:
          • Site Public Contact
          • 电话号码:212-639-7592
      • Middletown、New Jersey、美国、07748
        • 招聘中
        • Memorial Sloan Kettering Monmouth
        • 首席研究员:
          • Steven M. Horwitz
        • 接触:
          • Site Public Contact
          • 电话号码:212-639-7592
      • Montvale、New Jersey、美国、07645
        • 招聘中
        • Memorial Sloan Kettering Bergen
        • 首席研究员:
          • Steven M. Horwitz
        • 接触:
          • Site Public Contact
          • 电话号码:212-639-7592
    • New York
      • Commack、New York、美国、11725
        • 招聘中
        • Memorial Sloan Kettering Commack
        • 首席研究员:
          • Steven M. Horwitz
        • 接触:
          • Site Public Contact
          • 电话号码:212-639-7592
      • Harrison、New York、美国、10604
        • 招聘中
        • Memorial Sloan Kettering Westchester
        • 首席研究员:
          • Steven M. Horwitz
        • 接触:
          • Site Public Contact
          • 电话号码:212-639-7592
      • Mineola、New York、美国、11501
        • 暂停
        • NYU Langone Hospital - Long Island
      • New York、New York、美国、10032
        • 招聘中
        • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
        • 首席研究员:
          • Jennifer E. Amengual
        • 接触:
      • New York、New York、美国、10065
        • 招聘中
        • Memorial Sloan Kettering Cancer Center
        • 首席研究员:
          • Steven M. Horwitz
        • 接触:
          • Site Public Contact
          • 电话号码:212-639-7592
      • New York、New York、美国、10065
        • 暂停
        • NYP/Weill Cornell Medical Center
      • New York、New York、美国、10016
        • 暂停
        • Laura and Isaac Perlmutter Cancer Center at NYU Langone
      • Uniondale、New York、美国、11553
        • 招聘中
        • Memorial Sloan Kettering Nassau
        • 首席研究员:
          • Steven M. Horwitz
        • 接触:
          • Site Public Contact
          • 电话号码:212-639-7592
    • Ohio
      • Columbus、Ohio、美国、43210
        • 招聘中
        • Ohio State University Comprehensive Cancer Center
        • 接触:
        • 首席研究员:
          • Jonathan E. Brammer
    • Virginia
      • Richmond、Virginia、美国、23298
        • 招聘中
        • VCU Massey Comprehensive Cancer Center
        • 首席研究员:
          • Bruce O. Hough
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed CD2+, CD3+, or CD4+ acute, lymphoma or poor-risk chronic subtypes of ATLL including previously untreated or previously treated individuals who have received no more than 1 previous cycle of EPOCH, cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP), or cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE)

  • Patients previously treated with azidothymidine (AZT), interferon (IFN), bexarotene, or mogamulizumab are eligible. Patients with stable disease at high risk of relapse from prior non-combination chemotherapy containing treatment are eligible to participate

  • Documentation of HTLV infection by enzyme-linked immunosorbent assay (ELISA) in individuals with confirmation of HTLV-1 infection (by immunoblot or polymerase chain reaction [PCR]) or a consistent clinical picture (including two of three of: 1) CD4+ leukemia or lymphoma, 2) hypercalcemia, and/or 3) Japanese, Caribbean, or South American birthplace) is required for enrollment. Confirmation of HTLV-1 infection is required to continue the subject on protocol after the first cycle of therapy. Patients will be enrolled based on reports from local or referral labs (e.g., Mayo Clinic or LabCorp). Confirmation will be performed by Ratner Lab at Washington University, retrospectively, but this is not a Clinical Laboratory Improvement Amendments (CLIA) assay and is not reimbursed by insurance

  • Age ≥ 18 years

    • Because no dosing or adverse event (AE) data are currently available on the use of lenalidomide in combination with EPOCH in patients < 18 years of age, children are excluded from this study, but will be eligible for future pediatric trials
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)

  • Absolute neutrophil count >= 1,000/mm^3 unless decreased due to bone marrow (BM) involvement with lymphoma

  • Platelets >= 100,000/mm^3 unless decreased due to BM involvement with lymphoma

  • Total bilirubin =< 1.5 x institutional upper limit of normal (ULN), if potentially due to lymphoma, in the dose-expansion cohort, the first cycle may be given without lenalidomide and if transaminitis and bilirubinemia improves to meet parameters, participant may be enrolled

  • Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 x institutional ULN, if potentially due to lymphoma, in the dose-expansion cohort, the first cycle may be given without lenalidomide and if transaminitis and bilirubinemia improve to meet parameters, participant may be enrolled

  • Creatinine =< institutional ULN OR glomerular filtration rate (GFR) >= 60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal

  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated

  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load

  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression

  • Patients with new or progressive brain metastases (active brain metastases) or leptomeningeal disease are eligible if the treating physician determines that immediate CNS specific treatment is not required and is unlikely to be required during the first cycle of therapy

  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial

  • Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better

  • Patients must have a life expectancy > 12 weeks

  • Patients must have no serious active infection requiring therapy at the time of study entry

  • Patients must not require the concurrent use of chemotherapy, interferon, zidovudine, arsenic, radiation therapy, or other specific anti-tumor therapy, during the course of this study

  • The effects of lenalidomide on the developing human fetus are unknown. Immunodulatory derivative (immunomodulatory imide drug [IMiD]) agents as well as other therapeutic agents used in this trial are known to be teratogenic. Females of child-bearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU/mL within 10-14 days prior to, and again within 24 hours of starting lenalidomide, and must either commit to continued abstinence from heterosexual intercourse or begin two acceptable methods of birth control, one highly effective method and one additional effective method at the same time, at least 28 days before she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. All patients must be counselled at a minimum of every 28 days about pregnancy precautions and risk of fetal exposure. Should a woman become pregnant or suspect she is pregnant while she or her partner are participating in this study, she should inform her treating physician immediately. FCBP must use adequate contraception for at least 28 days after discontinuation from study. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for at least 28 days after discontinuation from study

  • Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible

Exclusion Criteria:

  • Patients that have received prior IMiDs for treatment of ATLL
  • Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
  • Patients who have not recovered to grade 1 or better from AEs due to prior anti-cancer therapy (not including cycle 1 of EPOCH, CHOP, or CHOPE if received off protocol) within 14 days prior to enrollment, with the exception of alopecia
  • Patients who are receiving any other investigational agents or have received them within 14 days prior to enrollment
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to lenalidomide or other agents used in study. Anaphylactic reactions including death have been reported with cyclophosphamide. Possible cross-sensitivity with other alkylating agents can occur
  • Patients unable to take aspirin or prophylactic doses of low molecular weight heparin or direct oral anticoagulants
  • Patients with urinary outflow obstruction (contraindication for cyclophosphamide)
  • Patients with any form of demyelinating disease should not be given vincristine sulfate injection
  • Patients with uncontrolled intercurrent illness
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements
  • Pregnant women are excluded from this study because lenalidomide is an IMiD agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with lenalidomide, breastfeeding should be discontinued if the mother is treated with lenalidomide. These potential risks may also apply to other agents used in this study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment (lenalidomide, EPOCH)

See Detailed Description.

Given IV

其他名称:
  • 胞毒素
  • CTX
  • (-)-环磷酰胺
  • 2H-1,3,2-氧氮杂膦,2-[双(2-氯乙基)氨基]四氢-,2-氧化物,一水合物
  • 卡洛生
  • 环磷酰胺
  • 环草醛
  • 克拉芬
  • CP一水合物
  • 循环电池
  • 环胚素
  • 环爆碱
  • 环磷酰胺一水合物
  • 环磷烷
  • 环磷脂
  • 环素
  • 环孢菌素
  • 胞磷
  • 胞磷烷
  • 磷脂龙
  • Genoxal
  • Genuxal
  • 雷多西那
  • 米托生
  • 新星
  • 重免疫
  • 赛克磷酰胺
  • WR- 138719
  • 阿斯塔B 518
  • B-518
  • WR-138719
  • 乙518
  • B518
  • WR 138719
  • WR138719
  • Frindovyx

Given IV

其他名称:
  • 阿霉素
  • 5,12-并萘二酮,10-[(3-氨基-2,3,6-三脱氧-α-L-来氧代-己吡喃糖基)氧基]-7,8, 9,10-四氢-6,8,11-三羟基-8-(羟基乙酰基)-1-甲氧基-, 盐酸盐, (8S-cis)- (9CI)
  • 广告管理公司
  • 盐酸阿霉素
  • 阿霉素 PFS
  • 阿霉素RDF
  • 阿霉素,盐酸盐
  • Adriblastina
  • 阿得拉碱
  • 阿地美达
  • 氯霉素
  • DOX
  • DOXO细胞
  • 多索伦
  • 阿霉素盐酸盐
  • 农杆菌
  • FI 106
  • FI-106
  • 羟基柔红霉素
  • 橡胶
  • FI106

Given PO

其他名称:
  • 达美松
  • 奥拉松
  • .delta.1-可的松
  • 1, 2-脱氢可的松
  • 阿达松
  • 皮质醇
  • 达考汀
  • 德考坦
  • 去氧硫醇
  • 德克顿
  • Delta 1-可的松
  • 三角穹顶
  • 三角可烯
  • 三角可的松
  • 三角洲脱氢可的松
  • 德尔蒂森
  • 三角洲
  • 经济松
  • 利沙克特
  • 美保生-F
  • 麦考坦
  • 奥菲索罗纳
  • 帕纳福特
  • 松脂-S
  • 伞骨
  • Perrigo 泼尼松
  • 预测
  • 泼尼松-M
  • 泼尼可特
  • 泼尼地布
  • 泼尼龙加
  • 预付款
  • 泼尼松 Intensol
  • 泼尼松
  • 泼尼通
  • 普罗米芬
  • 雷约斯
  • 伺服松
  • SK-泼尼松

Given PO

其他名称:
  • CC-5013
  • 来那度胺
  • CC5013
  • 疾控中心 501
  • CC 5013

Undergo bone marrow biopsy

其他名称:
  • 骨髓活检
  • 活组织检查,骨髓

Given IV

其他名称:
  • 致癌素
  • 基克里斯汀
  • 硫酸亮绿新碱
  • 硫酸白新碱
  • 长春
  • 长春甙
  • 万可乐
  • 硫酸长春新碱

Undergo ECHO

其他名称:
  • 超声心动图
  • 欧共体

Undergo MUGA

其他名称:
  • 血池扫描
  • 平衡放射性核素血管造影
  • 门控血池成像
  • 穆加
  • 放射性核素脑室造影
  • 导航导航仪
  • 司马扫描
  • 同步多门采集扫描
  • 穆加扫描
  • 多门控采集扫描
  • 放射性核素脑室造影扫描
  • 门控心池扫描
  • RNV扫描

Given IV

其他名称:
  • 去甲基鬼臼毒素乙苷
  • EPEG
  • 拉斯特
  • 拓扑萨
  • 韦贝斯
  • 副总裁 16
  • 副总裁 16-213
  • VP-16
  • VP-16-213
  • VP16
  • 副总裁 16213
  • VP-16213
  • VP16213

Undergo PET/CT

其他名称:
  • 医学成像、正电子发射断层扫描
  • 宠物
  • 宠物扫描
  • 正电子发射断层扫描
  • PT
  • 正电子发射断层扫描(程序)

Undergo PET/CT or CT

其他名称:
  • CT
  • 猫
  • 电脑扫描
  • 计算机轴向断层扫描
  • 计算机断层扫描
  • CT扫描
  • 断层扫描
  • 计算机轴向断层扫描(程序)
  • 计算机断层扫描 (CT) 扫描
  • 诊断猫扫描
  • 诊断猫扫描服务类型

Undergo tissue and blood sample collection

其他名称:
  • 生物样本采集
  • 收集的生物样本
  • 标本采集
  • 样本收集

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Maximum tolerated dose (MTD)
大体时间:Up to the end of induction therapy

Will determine the MTD for lenalidomide in combination with etoposide, prednisone, vincristine sulfate (Oncovin), cyclophosphamide, and doxorubicin hydrochloride (hydroxydaunorubicin hydrochloride) (EPOCH) chemotherapy.

Up to the end of induction therapy

次要结果测量

结果测量
措施说明
大体时间
Overall response rate
大体时间:Up to 2 years after completion of study treatment

Will be summarized using descriptive statistics. Binomial proportions and their 95% confidence intervals will be used to estimate the response rates of therapy.

Up to 2 years after completion of study treatment
Duration of response
大体时间:From the time measurement criteria are met for complete response or partial response until the first date that recurrent or progressive disease is objectively documented, assessed up to 2 years after completion of study treatment

Will be summarized using descriptive statistics. The Kaplan-Meier method will be used to evaluate the response duration.

From the time measurement criteria are met for complete response or partial response until the first date that recurrent or progressive disease is objectively documented, assessed up to 2 years after completion of study treatment
Progression-free survival
大体时间:Up to 2 years after completion of study treatment

Profession-free survival will be determined by the number of weeks from the time of initiation of therapy until there is evidence of tumor progression by acute T-cell leukemia (ATL) response criteria of Tuskasaki, 2009.

Up to 2 years after completion of study treatment
Overall survival
大体时间:Up to 2 years after completion of study treatment

Over survival will be determined by the number of week of weeks from the time of initiation of therapy until death.

Up to 2 years after completion of study treatment
T-cell receptor pathway gene mutational spectrum
大体时间:Up to 2 years after completion of study treatment

T-cell receptor pathway gene mutation will be determined by targeted next-generation sequence after hybridization to specific oligonucleotide capture probes corresponding to the sequence most commonly mutation in ATL as defined by Kataoka et al, 2015.

Up to 2 years after completion of study treatment
Human T-cell leukemia virus type 1 (HTLV-1) proviral deoxyribonucleic acid and ribonucleic acid loads
大体时间:Up to 2 years after completion of study treatment

Analysis of variance methods will be used to evaluate the effects of treatment and time on the viral load measurements, as well as measurements of viral transcripts.

Up to 2 years after completion of study treatment
HTLV-1 clonality
大体时间:Up to 2 years after completion of study treatment

HTLV-1 clonality will be determined by next generation sequence analysis of viral integration sites resulting in a distribution of the number of reads for each integration site plotted per integration site, as described by Gillet et al. 2011.

Up to 2 years after completion of study treatment
Incidence of toxicities
大体时间:Up to the end of induction therapy

The incidence of toxicities will be estimated using the binomial proportion and its 95% confidence interval.

Up to the end of induction therapy

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Lee Ratner、Yale University Cancer Center LAO

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2021年8月31日

初级完成 (估计的)

2027年6月30日

研究完成 (估计的)

2027年6月30日

研究注册日期

首次提交

2020年3月6日

首先提交符合 QC 标准的

2020年3月6日

首次发布 (实际的)

2020年3月9日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • NCI-2020-01535
  • UM1CA186689 (美国 NIH 拨款/合同)
  • NCI-2020-01535 (注册表标识符:CTRP (Clinical Trial Reporting Program))
  • 10335 (其他标识符:CTEP)
  • UM1CA186704 (美国 NIH 拨款/合同)
  • 10335 (其他标识符:Yale University Cancer Center LAO)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅